Associazione Angela Serra per la ricerca sul cancro

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Associazione Angela Serra per la ricerca sul cancro sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials 1 currently recruiting 2 completed upper quartile by trial count

Associazione Angela Serra per la ricerca sul cancro: 3 sponsored US clinical trials, 1 recruiting.

Associazione Angela Serra per la ricerca sul cancro sponsors 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. The most-studied condition in this pipeline is Lymphoma, T-Cell, Peripheral, with 1 trials.

Upper-quartile sponsor footprint

Associazione Angela Serra per la ricerca sul cancro sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Associazione Angela Serra per la ricerca sul cancro pipeline

1 recruiting of 3 indexed (33% open); 2 completed (67%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Lymphoma, T-Cell, Peripheral (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Associazione Angela Serra per la ricerca sul cancro: open-pipeline peers nationwide

Peers matched on 3 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

Associazione Angela Serra per la ricerca sul cancro sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 246810 0%10%20%30%40% Total trials Recruiting share Associazione Angela Serra per la ricerca sul cancro10xBio22nd Century GroupAA SecordAAADRS Clinical Research CenterAadi BioscienceAaron CookAbivax S.A.Actuated Medical
Associazione Angela Serra per la ricerca sul cancro sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Associazione Angela Serra per la ricerca sul cancro sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

What to do with this Associazione Angela Serra per la ricerca sul cancro page

3 registered trials is a research-attention snapshot, not an endorsement of Associazione Angela Serra per la ricerca sul cancro or any single study.

  • 1 of Associazione Angela Serra per la ricerca sul cancro's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Lymphoma, T-Cell, Peripheral is the condition Associazione Angela Serra per la ricerca sul cancro studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lymphoma, T-Cell, Peripheral trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Associazione Angela Serra per la ricerca sul cancro pipeline card: 3 registered trials from official public datasets.Report a data error.